This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Good day, ladies and gentlemen. And welcome to the Urologix Incorporated Fiscal Year 2012 Second Quarter Conference Call. My name is Ann, and I will be your coordinator for today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. As a reminder, this conference is being recorded for replay purposes.
Certain information discussed during this conference call, including answers to your questions, may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those stated or implied in any forward-looking statements due to risks and uncertainties. A detailed discussion of risks and uncertainties maybe found in Urologix’s recent annual report on Form 10-K for the year ended June 30, 2011 and other documents filed with the Securities and Exchange Commission. Urologix disclaims any obligation to update any forward-looking statements made during the course of this call.
At this time, I will turn the call over to Mr. Stryker Warren, Jr., Chief Executive Officer. Please proceed, sir.
Stryker Warren Jr.
Thank you, Ann, and good afternoon to all those joining us today to discuss the company's results for the second quarter of fiscal year 2012. With me are Brian Smrdel, the company's Chief Financial Officer; and Greg Fluet, the company’s Executive Vice President and Chief Operating Officer.